GATA3 expression loss is linked to stage progression but is unrelated to prognosis in muscle-invasive urothelial carcinoma of the bladder

  • Henning Plage (Geteilte/r Erstautor/in)
  • Henrik Samtleben (Geteilte/r Erstautor/in)
  • Sebastian Hofbauer
  • Kira Kornienko
  • Sarah Weinberger
  • Paul Giacomo Bruch
  • Sefer Elezkurtaj
  • Florian Roßner
  • Simon Schallenberg
  • Martina Kluth
  • Maximilian Lennartz
  • Niclas C Blessin
  • Andreas H Marx
  • Margit Fisch
  • Michael Rink
  • Marcin Slojewski
  • Krystian Kaczmarek
  • Thorsten Ecke
  • Steffen Hallmann
  • Stefan Koch
  • Nico Adamini
  • Sarah Minner
  • Ronald Simon
  • Guido Sauter
  • Tobias Klatte
  • Thorsten Schlomm
  • David Horst
  • Henrik Zecha

Abstract

The transcription factor GATA binding protein 3 (GATA3) is commonly used in surgical pathology as a diagnostic marker to distinguish urothelial carcinomas from other cancer entities. However, the clinical relevance of GATA3 expression in urothelial bladder cancer is not completely clarified. In this study, we investigated GATA3 immunostaining on 2710 urothelial bladder carcinomas on a tissue microarray platform by using two different antibodies to better understand its impact in relation to pathological parameters of disease progression and patient outcome. Nuclear GATA3 immunostaining was regularly seen in normal urothelium and found in 74%/82% of interpretable urothelial neoplasms depending on the antibody used. Within pTa tumors, the rate of GATA3 positive tumors decreased with advancing grade. GATA3 positivity was seen in 98.6%/99.8% of pTaG2 low-grade, 98.6%/100% of pTaG2 high-grade, and 94.9%/99.2% of pTaG3 high-grade tumors (P = .0002). As compared to pTa tumors, GATA3 positivity was markedly less common in muscle-invasive urothelial carcinoma (59.9%/71.6%; P < .0001). Within pT2-4 cancers, high-level GATA3 immunostaining was associated with the presence of lymph node metastasis (P = .0034), and blood vessel (P = .0290) or lymphatic invasion (P = .0005) but unrelated to pT stage. GATA3 immunostaining results for both antibodies were not associated with overall survival in 586 patients treated by cystectomy for pT2-4 urothelial carcinoma. The results of our study identify GATA3 expression as a frequent event in noninvasive urothelial carcinomas with favorable tumor features. Loss of GATA3 immunostaining is linked with muscle-invasive disease but is largely unrelated to pathological parameters and patient prognosis.

Bibliografische Daten

OriginalspracheEnglisch
ISSN0046-8177
DOIs
StatusVeröffentlicht - 12.2022

Anmerkungen des Dekanats

Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.

PubMed 36152841